Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders
- 27 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (1) , 94-100
Abstract
Objectives: To identify predictive factors for lymphoproliferative disorders (LPDs) that persist after methotrexate withdrawal (Persistent-LPD) and the optimal treatment for rheumatoid arthritis (RA) after LPD regression. Methods: Among 3,666 patients with RA treated with methotrexate in our department from 2006 to 2017, 26 cases of LPD that regressed after methotrexate withdrawal (Regressive-LPD) and 25 cases of Persistent-LPD were compared. Multivariate logistic analysis was performed to identify predictive factors for Persistent-LPD. Retention rates of biological disease-modifying antirheumatic drugs (bDMARDs) were calculated using the Kaplan-Meier Method. Results: In Persistent-LPD, the incidence of diffuse large B-cell lymphoma was higher (76%). The overall 2-year survival rate was 83.9%: 95.8% for Regressive-LPD and 71.0% for Persistent-LPD. The International Prognostic Index (IPI) risk classification was useful for predicting Persistent-LPD. bDMARDs were introduced in 38 RA patients after LPD regression. Unadjusted retention rate of bDMARDs in the 51 LPD patients was significantly lower than that in the 1668 non-LPD RA patients in our bDMARD cohort (controls) (p = 0.029). The 1-year retention rates for bDMARDs were 69% and 64% for tocilizumab and abatacept, respectively vs. 46% for TNF-inhibitor (TNFi). Conclusion: Risk assessment using IPI predicted Persistent-LPD. After LPD regression, non-TNFi tended to have higher retention rates.Keywords
This publication has 21 references indexed in Scilit:
- Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate‐associated large B lymphoproliferative disordersHistopathology, 2015
- Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regressionEuropean Journal of Haematology, 2013
- Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritisLeukemia & Lymphoma, 2012
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritisArthritis Research & Therapy, 2008
- The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observationArthritis & Rheumatism, 2007
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Reversible Lymphomas Associated with Epstein-Barr Virus Occurring during Methotrexate Therapy for Rheumatoid Arthritis and DermatomyositisNew England Journal of Medicine, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITISJAMA, 1949